Published in J Virol on September 01, 1996
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol (2004) 8.99
Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol (2007) 4.45
Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. J Virol (2005) 2.89
Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage. J Virol (1998) 2.83
Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J Virol (1997) 2.75
Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J Virol (1998) 2.63
International network for comparison of HIV neutralization assays: the NeutNet report. PLoS One (2009) 2.03
Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. J Virol (2002) 1.97
Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. J Virol (2000) 1.96
Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1. J Virol (1998) 1.75
Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses. J Virol (2008) 1.73
Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development. J Virol (2001) 1.51
Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6. J Virol (2001) 1.35
Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes. J Virol (2000) 1.34
Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees. J Virol (1998) 1.21
Immunotyping of human immunodeficiency virus type 1 (HIV): an approach to immunologic classification of HIV. J Virol (1999) 1.15
International network for comparison of HIV neutralization assays: the NeutNet report II. PLoS One (2012) 0.99
Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies. J Virol (2014) 0.96
Study of the dynamics of neutralization escape mutants in a chimpanzee naturally infected with the simian immunodeficiency virus SIVcpz-ant. J Virol (1997) 0.89
Extent of antigenic diversity in the V3 region of the surface glycoprotein, gp120, of human immunodeficiency virus type 1 group M and consequences for serotyping. J Virol (1998) 0.87
Neutralization patterns and evolution of sequential HIV type 1 envelope sequences in HIV type 1 subtype B-infected drug-naive individuals. AIDS Res Hum Retroviruses (2008) 0.85
Superinfection by discordant subtypes of HIV-1 does not enhance the neutralizing antibody response against autologous virus. PLoS One (2012) 0.80
W-curve alignments for HIV-1 genomic comparisons. PLoS One (2010) 0.76
Murine Monoclonal Antibodies for Antigenic Discrimination of HIV-1 Envelope Proteins. Viral Immunol (2015) 0.75
Variable and conserved neutralization antigens of human immunodeficiency virus. Nature (1987) 5.29
Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J Virol (1991) 5.09
Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. J Virol (1993) 3.95
Phylogenetic analysis of gag genes from 70 international HIV-1 isolates provides evidence for multiple genotypes. AIDS (1993) 3.52
Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J Virol (1994) 3.32
Epitopes recognized by the neutralizing antibodies of an HIV-1-infected individual. J Immunol (1990) 2.57
Genetic diversity of the envelope glycoprotein from human immunodeficiency virus type 1 isolates of African origin. J Virol (1995) 2.48
Genomic cloning and complete sequence analysis of a highly divergent African human immunodeficiency virus isolate. J Virol (1994) 2.29
Two groups of rhinoviruses revealed by a panel of antiviral compounds present sequence divergence and differential pathogenicity. J Virol (1990) 2.19
Genetic analysis of human immunodeficiency virus type 1 strains from patients in Cyprus: identification of a new subtype designated subtype I. J Virol (1995) 1.98
Genetic variation of HIV type 1 in four World Health Organization-sponsored vaccine evaluation sites: generation of functional envelope (glycoprotein 160) clones representative of sequence subtypes A, B, C, and E. WHO Network for HIV Isolation and Characterization. AIDS Res Hum Retroviruses (1994) 1.97
Genotypic subtypes of HIV-1 in Cameroon. AIDS (1994) 1.89
Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins. Proc Natl Acad Sci U S A (1992) 1.77
Characterization of human immunodeficiency virus type 1 isolates from children in Romania: identification of a new envelope subtype. J Infect Dis (1994) 1.64
V3 region polymorphisms in HIV-1 from Brazil: prevalence of subtype B strains divergent from North American/European prototype and detection of subtype F. AIDS Res Hum Retroviruses (1994) 1.59
Subgroup G HIV type 1 isolates from Nigeria. AIDS Res Hum Retroviruses (1994) 1.40
Presence in India of HIV type 1 similar to North American strains. AIDS Res Hum Retroviruses (1994) 1.37
Genetic and phylogenetic analysis of env subtypes G and H in central Africa. AIDS Res Hum Retroviruses (1994) 1.34
Identification of an env G subtype and heterogeneity of HIV-1 strains in the Russian Federation and Belarus. AIDS (1994) 1.18
Linear versus conformational variation of V3 neutralization domains of HIV-1 during experimental and natural infection. AIDS (1989) 1.04
Reduced capacity of antibodies from patients infected with human immunodeficiency virus type 1 (HIV-1) group O to neutralize primary isolates of HIV-1 group M viruses. J Infect Dis (1995) 1.04
Presence of multiple genetic subtypes of human immunodeficiency virus type 1 proviruses in Uganda. AIDS Res Hum Retroviruses (1994) 1.03
Spectral mapping, a technique for classifying biological activity profiles of chemical compounds. Arzneimittelforschung (1976) 1.01
Molecular phylogeny of part of the env gene of HIV-1 strains isolated in Côte d'Ivoire. AIDS (1994) 0.98
Cross-neutralizing antibodies to HIV-1ANT70 and HIV-1IIIB in sera of African and Belgian HIV-1-infected individuals. AIDS (1994) 0.79
Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men. Lancet (1989) 11.39
Cofactors in male-female sexual transmission of human immunodeficiency virus type 1. J Infect Dis (1991) 7.05
Genomic heterogeneity of AIDS retroviral isolates from North America and Zaire. Science (1985) 6.31
AIDS in Africa: an epidemiologic paradigm. Science (1986) 5.88
Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature (1990) 5.70
The right not to know HIV-test results. Lancet (1995) 5.16
Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: a randomised trial. Lancet (1999) 5.00
AIDS virus infection in Nairobi prostitutes. Spread of the epidemic to East Africa. N Engl J Med (1986) 4.68
Human immunodeficiency virus infection among men with sexually transmitted diseases. Experience from a center in Africa. N Engl J Med (1988) 4.55
Global prevalence and incidence estimates of selected curable STDs. Sex Transm Infect (1998) 4.39
Condom promotion, sexually transmitted diseases treatment, and declining incidence of HIV-1 infection in female Zairian sex workers. Lancet (1994) 4.38
Selective differential human blood bilayer media for isolation of Gardnerella (Haemophilus) vaginalis. J Clin Microbiol (1982) 4.28
Nucleotide sequence of a 16S ribosomal RNA gene from Neisseria gonorrhoeae. Nucleic Acids Res (1988) 4.19
Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J Mol Biol (1994) 3.85
Phylogenetic analysis of gag genes from 70 international HIV-1 isolates provides evidence for multiple genotypes. AIDS (1993) 3.52
The interaction of HIV infection and other sexually transmitted diseases: an opportunity for intervention. AIDS (1989) 3.48
Identification of Gardnerella (Haemophilus) vaginalis. J Clin Microbiol (1982) 2.96
The ecology of gonococcal plasmids. J Gen Microbiol (1979) 2.87
Clinical algorithms for the screening of women for gonococcal and chlamydial infection: evaluation of pregnant women and prostitutes in Zaire. Clin Infect Dis (1993) 2.68
Isolation of Marburg-like virus from a case of haemorrhagic fever in Zaire. Lancet (1977) 2.65
Retrospective seroepidemiology of AIDS virus infection in Nairobi populations. J Infect Dis (1987) 2.63
Epidemiology and treatment of penicillinase-producing Neisseria gonorrhoeae. Sex Transm Dis (1979) 2.57
Genetic diversity of the envelope glycoprotein from human immunodeficiency virus type 1 isolates of African origin. J Virol (1995) 2.48
Acquired immunodeficiency syndrome in a heterosexual population in Zaire. Lancet (1984) 2.43
Hemorrhagic fever with renal syndrome. Prog Med Virol (1989) 2.38
An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk] [1,4]benzodiazepin-2 (1H)-one and -thione derivatives. Proc Natl Acad Sci U S A (1991) 2.37
Bronchopulmonary infection due to beta-lactamase-producing Branhamella catarrhalis treated with amoxycillin/clavulanic-acid. Lancet (1978) 2.37
Intense superradiant x rays from a compact source using a nanocathode array and emittance exchange. Phys Rev Lett (2012) 2.32
Antibiotic susceptibility of Neisseria gonorrhoeae strains from Europe and Africa. Antimicrob Agents Chemother (1979) 2.31
Genomic cloning and complete sequence analysis of a highly divergent African human immunodeficiency virus isolate. J Virol (1994) 2.29
Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother (2012) 2.26
Prophylaxis of gonococcal and chlamydial ophthalmia neonatorum. A comparison of silver nitrate and tetracycline. N Engl J Med (1988) 2.20
Declining trends in some sexually transmitted diseases in Belgium between 1983 and 1989. Genitourin Med (1991) 2.17
Hepatitis C virus genotyping by means of 5'-UR/core line probe assays and molecular analysis of untypeable samples. Virus Res (1995) 2.14
The international epidemiology of AIDS. Sci Am (1988) 2.08
Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob Agents Chemother (2001) 2.00
Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob Agents Chemother (2006) 1.97
Ethics of placebo-controlled trials of zidovudine to prevent the perinatal transmission of HIV in the Third World. N Engl J Med (1998) 1.95
Mother-to-child transmission of human immunodeficiency virus type 1: report from the Nairobi Study. J Infect Dis (1994) 1.94
Antimicrobial therapy of chancroid: an evaluation of five treatment regimens correlated with in vitro sensitivity. Sex Transm Dis (1983) 1.92
Prostitutes are a major reservoir of sexually transmitted diseases in Nairobi, Kenya. Sex Transm Dis (1985) 1.91
Sequence analysis of a highly divergent HIV-1-related lentivirus isolated from a wild captured chimpanzee. Virology (1996) 1.91
Effectiveness of norfloxacin and ofloxacin for treatment of gonorrhoea and decrease of in vitro susceptibility to quinolones over time in Rwanda. Genitourin Med (1993) 1.89
Genotypic subtypes of HIV-1 in Cameroon. AIDS (1994) 1.89
Filoviridae: a taxonomic home for Marburg and Ebola viruses? Intervirology (1982) 1.89
Condom use and HIV infection among prostitutes in Zaire. N Engl J Med (1987) 1.82
Detection of human immunodeficiency virus type 1 (HIV-1) in heel prick blood on filter paper from children born to HIV-1-seropositive mothers. J Clin Microbiol (1994) 1.81
In vitro activities of the spectinomycin analog U-63366 and four quinolone derivatives against Neisseria gonorrhoeae. Antimicrob Agents Chemother (1984) 1.80
The puzzle of HIV-1 subtypes in Africa. AIDS (1997) 1.80
Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1. J Virol (1998) 1.75
Role of the laboratory in ensuring global access to ARV treatment for HIV-infected children: consensus statement on the performance of laboratory assays for early infant diagnosis. Open AIDS J (2008) 1.74
Towards developing a diagnostic algorithm for Chlamydia trachomatis and Neisseria gonorrhoeae cervicitis in pregnancy. Genitourin Med (1990) 1.74
Characterization of Dobrava virus: a Hantavirus from Slovenia, Yugoslavia. J Med Virol (1992) 1.73
Confirmation and differentiation of antibodies to human immunodeficiency virus 1 and 2 with a strip-based assay including recombinant antigens and synthetic peptides. Clin Chem (1991) 1.73
Branhamella (Neisseria) catarrhalis as pathogen. Lancet (1977) 1.73
Isolation and characterization of a new chimpanzee lentivirus (simian immunodeficiency virus isolate cpz-ant) from a wild-captured chimpanzee. AIDS (1992) 1.72
Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc Natl Acad Sci U S A (1993) 1.71
A taxonomic study of Gardnerella vaginalis (Haemophilus vaginalis) Gardner and Dukes 1955. J Gen Microbiol (1980) 1.69
Time to detection of the growth of Mycobacterium tuberculosis in MGIT 960 for determining the early bactericidal activity of antituberculosis agents. Eur J Clin Microbiol Infect Dis (2010) 1.67
Distribution of eight serotypes of Ureaplasma urealyticum in cases of non-gonococcal urethritis and of gonorrhoea, and in healthy persons. Br J Vener Dis (1976) 1.67
Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. J Mol Biol (1996) 1.65
Association of cervical ectopy with heterosexual transmission of human immunodeficiency virus: results of a study of couples in Nairobi, Kenya. J Infect Dis (1991) 1.62
HIV infection among lower socioeconomic strata prostitutes in Nairobi. AIDS (1990) 1.62
The etiology of genital ulceration in Rwanda. Sex Transm Dis (1989) 1.61
Isolation and partial characterization of an unusual human immunodeficiency retrovirus from two persons of west-central African origin. J Virol (1990) 1.61
Maternal human immunodeficiency virus-1 infection and pregnancy outcome. Obstet Gynecol (1994) 1.60
In-vitro activity of Ro-15-8074, a new oral cephalosporin. J Antimicrob Chemother (1985) 1.59
Antiviral and lung protective activity of a novel respiratory syncytial virus fusion inhibitor in a mouse model. Eur Respir J (2010) 1.59
Structures of poliovirus complexes with anti-viral drugs: implications for viral stability and drug design. Curr Biol (1994) 1.57
The vaginal microbial flora in non-specific vaginitis. Eur J Clin Microbiol (1982) 1.56
Etiology of genital ulcerations in Swaziland. Sex Transm Dis (1983) 1.55
Antimicrobial susceptibility and characterization of outer membrane proteins of Haemophilus ducreyi isolated in Thailand. J Clin Microbiol (1985) 1.54
HIV seroprevalence among hospital workers in Kinshasa, Zaire. Lack of association with occupational exposure. JAMA (1986) 1.54
Subtype G and multiple forms of A/G intersubtype recombinant human immunodeficiency virus type 1 in Nigeria. Virology (1999) 1.54
Myocardial steal produced by coronary vasocilation in chronic coronary artery occlusion. Basic Res Cardiol (1973) 1.53
Rehabilitation and acute exacerbations. Eur Respir J (2011) 1.53
Resistant gonococcus from the ivory coast. Lancet (1977) 1.53
Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nat Struct Biol (1995) 1.53
Detection of diverse variants of human immunodeficiency virus-1 groups M, N, and O and simian immunodeficiency viruses from chimpanzees by using generic pol and env primer pairs. J Infect Dis (2000) 1.52
Activity in vitro of ten antimicrobial agents against Neisseria gonorrhoeae. A study of the correlation between the sensitivities. Br J Vener Dis (1976) 1.52
A TIBO derivative, R82913, is a potent inhibitor of HIV-1 reverse transcriptase with heteropolymer templates. Antiviral Res (1991) 1.51
Infection with HIV as a risk factor for adverse obstetrical outcome. AIDS (1990) 1.51
Detection of phylogenetically diverse human immunodeficiency virus type 1 groups M and O from plasma by using highly sensitive and specific generic primers. J Clin Microbiol (1999) 1.51